[PDF][PDF] Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
IE Krop, M Beeram, S Modi, SF Jones, SN Holden… - J Clin Oncol, 2010 - academia.edu
J Clin Oncol, 2010•academia.edu
Purpose Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to
specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive cells. This
first-in-human study of T-DM1 evaluated safety, pharmacokinetics, and preliminary activity of
T-DM1 in patients with advanced HER2-positive breast cancer.
specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive cells. This
first-in-human study of T-DM1 evaluated safety, pharmacokinetics, and preliminary activity of
T-DM1 in patients with advanced HER2-positive breast cancer.
Purpose
Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive cells. This first-in-human study of T-DM1 evaluated safety, pharmacokinetics, and preliminary activity of T-DM1 in patients with advanced HER2-positive breast cancer.
academia.edu